Celcuity (CELC) Income from Continuing Operations (2016 - 2026)
Celcuity's (CELC) quarterly Income from Continuing Operations came in at 50973000.0 in Q4 2025, down 39.07% YoY from 83657071.11 in Q4 2024, and down 16.37% on a QoQ basis from 43804000.0 in Q3 2025.
Powered by 
Analysis
Celcuity (CELC) Income from Continuing Operations (2016 - 2026) Analysis & Trends
Celcuity (CELC) has 10 years of Income from Continuing Operations data on file, last reported at 50973000.0 in Q4 2025.
- Quarterly Income from Continuing Operations fell 39.07% year-over-year to 50973000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 177042000.0 (down 58.39% YoY) and the FY2025 annual result came in at 139863000.0, down 24.38% from the prior year.
- Income from Continuing Operations retreated to 50973000.0 in Q4 2025, from 43804000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 2791668.0 in Q1 2021 to a low of 50973000.0 in Q4 2025.
- A 5-year average of 21128771.1 and a median of 16496113.5 in 2023 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2021 — Income from Continuing Operations slumped 1104.06% — and 2022, when it rose 29.02%.
- Tracing CELC's Income from Continuing Operations over 5 years: stood at 6753500.0 in 2021, then plunged by 71.49% to 11581346.0 in 2022, then slumped by 62.75% to 18848472.0 in 2023, then plunged by 94.46% to 36653000.0 in 2024, then plunged by 39.07% to 50973000.0 in 2025.
- The last three Income from Continuing Operations figures came in at 50973000.0 (Q4 2025), 43804000.0 (Q3 2025), and 45268000.0 (Q2 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.62 Bn | 131.77 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.73 Bn | 77.73 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.53 Bn | 58.35 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 58.23 Bn | 53.09 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.03 Bn | 34.93 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.50 Bn | 32.19 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.52 Bn | 27.68 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Celcuity | 5.19 Bn | 5.19 Bn | - | -78.86 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -78.86 Mn |
| Dec 31, 2025 | -50.97 Mn |
| Sep 30, 2025 | -43.80 Mn |
| Jun 30, 2025 | -45.27 Mn |
| Mar 31, 2025 | -37.00 Mn |
| Dec 31, 2024 | -36.65 Mn |
| Sep 30, 2024 | -29.79 Mn |
| Jun 30, 2024 | -23.72 Mn |
| Mar 31, 2024 | -21.61 Mn |
| Dec 31, 2023 | -18.85 Mn |
| Sep 30, 2023 | -18.40 Mn |
| Jun 30, 2023 | -14.59 Mn |
| Mar 31, 2023 | -11.94 Mn |
| Dec 31, 2022 | -11.58 Mn |
| Sep 30, 2022 | -10.89 Mn |
| Jun 30, 2022 | -9.96 Mn |
| Mar 31, 2022 | -7.93 Mn |
| Dec 31, 2021 | -6.75 Mn |
| Sep 30, 2021 | -6.03 Mn |
| Jun 30, 2021 | -14.03 Mn |